Pharmaceuticals, Biotechnology and Life Sciences
Bayer has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive advanced or recurrent solid tumors.
AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .
Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved…
GlaxoSmithKline got the approval for shingles prevention, and post-herpetic neuralgia (PHN) vaccine Shingrix, in Europe, while in Japan it was registered…
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s treatment for type 2 diabetes adult patients, new…
N4 Pharma will present its Nuvec in a meeting with japanese companies in February. The UK pharmaceutical company will be…
AstraZeneca and its global biologics research and development arm, MedImmune, said on Friday that the Japanese Ministry of Health, Labour…
AstraZeneca and Merck have announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg…
Merck’s anti PD-1 therapy Keytruda has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) to treat…
An ageing population, a growing generics market and liberalization of Over-The-Counter medicines make Japan an attractive destination for investments, particularly as the pharma industry undergoes legislative change, with the Government’s bid to cut healthcare expenditure.